OGT’s RNA-based SureSeq Myeloid Fusion Panel is a new-generation sequencing tool for identifying fusion genes implicated in acute myeloid leukemia. The company claims the new panel addresses the latest research recommendations, identifying over 30 key disease-associated fusions in AML in a single assay. The panel is compatible with OGT’s existing end-to-end Universal NGS Complete Workflow Solution and software to minimize hands-on time and provide analysis without the need for additional bioinformatics resources. The launch expands the company’s portfolio to offer more NGS solutions for hematological malignancies and solid tumor cancer research.
